13. Meningococcal disease

Incidence and serotypes

The prevalence of meningococcal groups varies geographically. The highest burden of disease occurs in sub-Saharan Africa, where despite a dramatic fall in Group A disease following introduction of a Group A conjugate vaccine, in this ‘meningitis belt’ epidemics continue with around 30,000 cases reported annually, now including Group W.

The incidence in Canada, the US and Europe varies substantially from 0.2 to 3 per 100,000 persons per year.[3] Group B has become the predominant capsular group in Europe, Americas and Australia, with incidence typically highest in children aged under 2 years.[4] Group C disease has almost disappeared in countries with universal immunisation programmes, but outbreaks have been observed in men who have sex with men in the US and Europe.

Since 2009 there has been an emerging global incidence of Group W disease, initially in the United Kingdom and South America. Australia has experienced a rapid increase in Group W cases since 2013 with New Zealand also seeing a rapid increase in cases since 2017. Like group C clonal complex ST11 strains, group W ST11 strains have enhanced virulence. Higher rates of carriage of these ST11 strains has been noted within age groups where invasive group W disease is more prevalent (infants and the elderly).[5]

Some parts of the world, particularly Scandinavia, have reported an increase in group Y disease. In other regions, there is evidence of colonisation, but disease caused by group Y is rare. Patients with group Y strain disease are more likely to develop pneumonia and to be elderly.[3, 4]

This emergence of group W and Y strains has led to meningococcal C vaccines being replaced by quadrivalent (group A, C, W, Y) meningococcal conjugate vaccines (MenACWY).

Risk groups

The highest incidence of meningococcal disease occurs in children aged under 5 years (especially under 2 years) with a secondary peak in older adolescents (15–19 years).The age distribution for groups W and Y is more likely to include older people that for B and C. A pooled overall case-fatality rate of 8.3 percent (range 4.1–20 percent) is reported internationally, varying by group and age.[6]

Most infection occurs in healthy people, but those with certain rare immune deficiencies (of terminal components of complement (C5–9) or properdin) or asplenia are at much higher risk, particularly of recurrent meningococcal disease. Individuals with infection caused by groups other than A, B, C, W, Y and untypeable strains or who experience recurrent disease should be investigated.

Close contacts of primary cases of meningococcal infection are at increased risk of developing infection, such as the case’s household,[7] early childhood education services, semi-closed communities, schools, correctional facilities and military recruit camps. Students living in hostel accommodation may also be at higher risk.[8, 9, 10] In health care settings, only those with close exposure to oropharyngeal secretions of patients with meningococcal disease (as may occur during intubation or resuscitation) and microbiology laboratory workers are considered to be at increased risk.

It is not possible to calculate the incubation period for meningococcal disease for sporadic cases. Secondary cases (ie, in contacts of known cases of meningococcal disease) usually occur within four days, but it can be up to 10 days. The infectivity of patients with meningococcal disease is markedly reduced after 24 hours of antibiotic therapy, although treatment with cefotaxime, ceftriaxone, rifampicin or ciprofloxacin is necessary to reliably eradicate nasopharyngeal carriage.

In high-income countries in the absence of immunisation, nasopharyngeal carriage of N. meningitidis occurs in approximately 10 percent of the overall population, rising from 2 percent in children aged under 4 years to a peak of 24.5 percent to 32 percent among 15–24-year-olds, then declining with increasing age.[3, 11] In adolescents and young adults, the overall and capsular group carriage vary between regions and age groups.[12] The relationship between risk factors for disease and those associated with carriage is incompletely understood.[3] Carriage prevalence does not predict the disease incidence nor the occurrence or severity of outbreaks, as most of the carried strains are non-encapsulated and do not cause disease.[3] Smoking, passive smoking, household crowding and upper respiratory tract infections increase carriage.

Incidence and mortality

From 1 January to 31 December 2023, there were 59 cases of meningococcal disease (52 confirmed cases), which was an increase from the same period in 2020 and 2021 but lower than in 2017, 2018, 2019 and 2022. Of the 15 cases aged under 5 years, 87 percent were of Māori and/or Pacific ethnicity. There was one death in an adult aged 20–29 years.[13]

For 2023, the notification rate for meningococcal disease was 1.1 cases per 100,000 population, with a total of 59 cases notified (52 laboratory confirmed; ESR, 12 July 2024). Cases remained significantly lower than the peak annual incidence rate of 16.7 per 100,000 for all ages and 200 per 100,000 in children under 12 months as experienced in 2001 during the meningococcal epidemic from 1991 to 2007. The epidemic was largely due to a single group B subtype (B:P1.7-2,4). The annual number of notified cases of meningococcal disease in New Zealand since 1970 is shown in Figure 13.1.[13]

For further details and reports of meningococcal disease in New Zealand refer to the ESR surveillance reports.

Figure 13.1: Notified cases of meningococcal disease, 1970–2023

Figure 13.2: Meningococcal disease notifications by group, 2014–2023

Internationally, meningococcal vaccination programmes were revolutionised by the development of conjugate vaccines, which allow vaccination in younger children and induced herd immunity when used in population-wide programmes due to reduced nasopharyngeal carriage (see section 1.4.3).

The quadrivalent (ACWY) conjugate vaccines contain group A, C, W, Y polysaccharides conjugated to tetanus toxoid protein. Previously used, polysaccharide-only vaccines provided three to five years’ protection in adults, but they are generally regarded as inferior to conjugate vaccines and are no longer approved for use in New Zealand. Those travelling to Africa, the Middle East and other areas with wide serogroup prevalence, including group A, require MenACWY vaccine for broad protection. In 2018, a multicomponent meningococcal group B recombinant vaccine (MenB, formerly abbreviated 4CMenB) was registered in New Zealand to protect against group B disease.

With the current New Zealand epidemiology, neither MenACWY nor MenB give protection across all prevailing meningococcal groups and both types of vaccine are recommended. The meningococcal vaccines registered and available are summarised in Table 13.3 below.

Meningococcal group B recombinant vaccine

Three years after initiation of the introduction of MenB to the national immunisation schedule in the UK, a 75 percent reduction in group B disease was reported in the vaccine-eligible age groups compared with a historical cohort.[14] With 88 percent coverage but a low number of cases (25), adjusted vaccine effectiveness for all group B strains was 59.1 percent (95% CI: -31.1–87.2) following two primary doses and one booster dose, with an estimated 277 cases prevented.[14] This research is ongoing.

Following MenB vaccination of adolescents aged 15-16 years in South Australian schools, there was an overall reduction of 71 percent (95% CI 15-90; p=0.02) in group B meningococcal disease cases aged 16–19 years: five cases in 2017–2018 (predicted 9.9 [95% predicted interval 3.9-17.5]) and one case in 2018–2019 (predicted 10.9 [4.4–19.1]).[15]

As was observed during college outbreaks in the US,[16, 17] in South Australia where MenB is administered in a school-based programme at age 15–18 years, MenB had no effect on disease-causing meningococcal carriage suggesting that vaccination of adolescents is unlikely to generate herd immunity.[18] A MenB vaccination campaign used during an isolated outbreak in a region of Québec, Canada outbreak demonstrated direct protection of 79 percent against outbreak strain group B disease and an overall impact of 86 percent in target groups with no herd effects.[19]

Cross-protection against meningococcal group W has been observed following vaccination of infants with MenB in the UK. Among age-cohorts that were fully and partially eligible to receive MenB, respectively, it was estimated that there were 69 percent (adjusted incidence rate ratio 0.31; 95% CI 0.2-0.67) and 52 percent (0.48; 0.28-0.81) fewer cases of group W disease than predicted in 2018/2019; this included direct and indirect protection over four years. An estimated 98 cases (95% CI 34-201) of group W disease were directly prevented in children aged under 5 years.[20] The researchers state that MenACWY conjugate vaccines would still be required for direct and indirect protection against those groups, since the degree of cross-protection is dependent on the expression of vaccine antigens on the meningococcal surface.[20]

There is limited data on its use in patients with chronic medical conditions and those immunocompromised by medication or disease, such as HIV infection or hereditary immune system defects. In a phase 3 clinical trial, children aged 2­–17 years showed good but reduced immunogenicity in those with immunocompromise.[21] Immunogenicity in children with asplenia and splenic dysfunction was similar to healthy children but reduced in children with complement deficiencies.[22]

The safety and efficacy of MenB in adults above 50 years of age have not been established.

Quadrivalent meningococcal conjugate vaccines

Clinical trial data use immunogenicity and bactericidal antibody titres as a proxy for efficacy. Effectiveness of conjugate meningococcal vaccination against laboratory-confirmed disease is difficult to assess due to the low incidence of cases, even during localised epidemics, such that data is limited around the effectiveness of the MenACWY vaccines. With the emergence of group W and Y strains, more countries have implemented mass campaigns and routine immunisation programmes to control outbreaks with MenACWY vaccines and can assess impact through disease incidence and carriage studies. The current evidence indicates that MenACWY (MenQuadfi) has similar or superior immunogenicity to other MenACWY vaccines; real-world effectiveness data is limited to date as it was first licensed in 2020.

Several phase II and III clinical trials have assessed the immunogenicity of the MenACWY vaccine, MenQuadfi. These studies have included healthy vaccine-naive toddlers aged from 12 months; vaccine-naïve older children and adolescents; booster doses in toddlers, children and adolescents following prior MenACWY or MenC vaccination; given concurrently with routine vaccines (DTaP-IPV-HepB/Hib, MMR, VV, PCV13, Tdap and HPV); and in adults aged over 56 years.[23] In all studies, robust antibody responses were observed in all groups, immunogenicity was non-inferior to comparator vaccines and booster responses were observed.

Bactericidal antibody responses in adults (aged 18-55 years) were two to six times greater in those vaccinated with MenQuadfi, compared those vaccinated with diphtheria-toxoid conjugated MenACWY (Menactra), and a higher proportion of participants had a positive seroresponse.[24]

One clinical trial observed lower antibody responses to FHA, PRN and FIM2/3 pertussis antigens but not pertussis toxin, when MenACWY was given concurrently with Tdap and HPV in adolescents compared with without MenACWY.[25] The clinical relevance is unknown and has been observed with other MenACWY vaccines.[23] No interference was documented with other vaccines. There is no published data to date on effectiveness or use in immunocompromised individuals.

The other MenACWY-T vaccine (Nimenrix) is registered in New Zealand for individuals from aged 6 weeks. Clinical trials showed that the vaccine elicited bactericidal antibodies against all four groups from age 2 months with acceptable reactogenicity and safety profile.[26]

There is no published data on effectiveness in older adults for these vaccines.

Transport according to the National Standards for Vaccine Storage and Transportation for Immunisation Providers 2017 (2nd edition).

Store at +2°C to +8°C. MenACWY vaccines and MenB should be protected from light. Do not freeze.

Reconstitution

The MenACWY vaccine, Nimenrix, must be reconstituted with the supplied diluent and used as soon as possible. The other meningococcal vaccines are fully liquid formulations and do not require reconstitution.

Meningococcal group B recombinant vaccine (MenB)

Each MenB (Bexsero) dose is 0.5 ml, administered by intramuscular injection (see section 2.2.3).

• For infants aged 8 weeks to 11 months, two doses are given with a minimum of eight weeks between doses, with a booster given at least six months after the second dose, from age 12 months.
• For toddlers aged 12­–23 months (at time of first dose) a primary course of two doses is given at least eight weeks apart. A booster dose is recommended from 12 to 23 months after dose two.
• For children aged from 2 years (at time of first dose) and adults, two doses are given at least eight weeks apart (see section 13.5.1 for reduced spacing). (Note: the safety and efficacy in individuals aged over 50 years have not been established, but no safety concerns are expected.)

Generally, the need for booster doses from the age 2 years or older at the time of their first dose has not been established. A booster dose can be considered for individuals at continued risk of exposure to meningococcal disease. Booster doses are funded five-yearly for some high-risk individuals (see Table 13.6).

MenB can be administered concurrently with other scheduled vaccines, in separate syringes and at separate sites (see section 2.2.7).

See section 13.5.1 for recommendations around antipyretic prophylaxis use with delivery in children aged under 2 years.

Quadrivalent meningococcal conjugate vaccines (MenACWY)

Each MenACWY dose is 0.5 mL, administered by intramuscular injection (see section 2.2.3).

MenACWY and MenC vaccines can be concurrently administered with other vaccines in separate syringes and at separate sites.

MenQuadfi

MenQuadfi is given as a single dose to individuals aged 12 months and over. See Table 13.6 for schedules and dosing for certain special groups.

A single booster dose may be given to adolescent and adults who have been primed with another MenACWY vaccine at least 4 years previously. There is currently no data available to indicate the need for or timing of a booster dose.

Nimenrix 

Nimenrix is approved for use in New Zealand for individuals from age 6 weeks.

• For infants aged under 12 months, two doses are given eight weeks apart, plus a booster at least six months after second dose, from age 12 months. Primary doses are funded for certain infants aged 6 weeks to under 12 months (see Table ‎13.6).
• Healthy infants aged 6 months to under 12 months, who are not immunocompromised, can be given one dose (unfunded) instead of two primary doses, plus a booster from age 12 months, at least eight weeks later.
• For adults and children from age 12 months, one dose is given (unfunded).
• Booster doses may be indicated in some individuals.

A primary course of MenB is recommended and funded for all children at ages 3 months, 5 months and a booster given at age 12 months. In an alternative approved schedule, MenB can be given at ages 2 months (ie, approved from 8 weeks) and 4 months with a booster at age 12 months; this would be outside the standard scheduled immunisation visits. Do not delay the 6-week vaccination event for the other Schedule vaccines.

For children at high risk of meningococcal disease aged younger than 8 weeks, to align with the routine schedule visit, MenB can be given at ages 6 weeks and 3 months. This is off-label use and requires a prescription for both events. No prescription is required if given as per the alternative schedule at ages 2 and 4 months.

A catch-up programme of MenB is funded for children aged 13 months to 59 months until 31 August 2025. All children eligible for meningococcal B catch-up should be vaccinated at the earliest opportunity. Give two doses 8 weeks apart. For children those aged 12 to under 24 months at time of their first dose, a further dose can be given from 12 to 24 months after second dose. If MenB is started before the age 5 years, then the funded course can be completed.

As an antipyretic, prophylactic paracetamol is recommended to be given up to 30 minutes prior to or immediately after MenB vaccination and give up to two further doses four to six hours apart for children aged under 2 years. Ibuprofen may be given as an alternative to paracetamol six to eight hourly (see section 13.7.1).

Meningococcal vaccines are funded in special circumstances, as described in the shaded section of Table ‎13.5; Table ‎13.6 shows the recommended dosing schedules.

See sections 4.2.5, 4.4 and 4.5 for more information about vaccination of special groups, including recommended immunisation schedules for high-risk individuals with certain medical conditions.

The meningococcal vaccines are recommended (but not funded) for other individuals at risk, as described in non-shaded rows in Table 13.5.

Before travel

There are areas of the world where the risk of meningococcal disease is increased. Nevertheless, the risk to travellers to the developing world has been estimated as being less than one in a million per month. Recurrent epidemics of meningococcal disease occur in the sub-Saharan ‘meningitis belt’, from Senegal in the west to Ethiopia in the east, usually during the dry season (December to June). Epidemics are occasionally identified in other parts of the world, including in Europe and the Americas. Generally, countries outside of Africa experience smaller outbreaks, but case-fatality rates can be high.

The preferred vaccines (MenACWY and/or MenB) for travel would be based on the epidemiology of the country. For website sources for information about meningococcal vaccines for travellers, see the WHO website. Quadrivalent meningococcal vaccine is a requirement for pilgrims to the Hajj.

Before moving into communal living situations

MenACWY and MenB are recommended and funded from age 13–25 years inclusively for individuals who will be living in communal accommodation within the next three months, or who are in their first year of living in communal accommodation (specifically, boarding school hostels, tertiary education halls of residence, military barracks, youth justice residences or prisons) as they are likely to be at higher risk of acquiring meningococcal infection. This includes children who turn 13 years of age while living in boarding school hostels.

Non-high-risk children and adolescents may be offered meningococcal vaccines. These vaccines are only funded for certain groups (see Table 13.4). Table ‎13.7 suggests the most appropriate ages for this, reflecting the known ages of increased risk. The predominant meningococcal strains in New Zealand in childhood are B, W and Y. With the current New Zealand epidemiology, neither MenACWY nor MenB give protection across all prevailing meningococcal groups and both types of vaccine are recommended. For those who are likely to travel, the broadest protection is preferable because of the differing serotype patterns between countries.

There are no reports of any adverse effects among pregnant women who have been vaccinated during pregnancy.[27] Meningococcal vaccines may be given in pregnancy and to those who are lactating, if indicated.[28, 29]

Meningococcal conjugate vaccines, MenC, MenACWY and MenB are funded for vaccination or re-vaccination of eligible individuals, as follows. See also section 4.3.

Quadrivalent meningococcal conjugate vaccines, MenACWY

• Age under 12 months – up to three doses (Nimenrix), plus booster (MenQuadfi) after age 12 months and every five years (as appropriate)
• Age from 12 months – up to two doses (MenQuadfi) plus booster every five years (as appropriate)

Primary vaccination plus booster doses of MenACWY (as age appropriate) are funded for individuals:

• pre- or post-splenectomy
• with functional or anatomic asplenia
• pre- or post-solid organ transplantation
• with complement deficiency (acquired or inherited)
• who are HIV-positive.

A maximum of two (MenQuadfi) or three (Nimenrix, depending on age of first dose) doses are funded for individuals:

• post-haematopoietic stem cell transplantation
• prior to planned and following immunosuppression for longer than 28 days.

Recombinant meningococcal B vaccine, MenB

• Age under 12 months – up to three doses, plus booster after age 12 months and every five years (as appropriate)
• Age from 12 – 23 months – up to two doses plus booster given 12 to 23 months after second dose, and booster every five years (as appropriate)
• Age from 2 years – up to two doses plus a booster every five years (as appropriate)

Primary vaccination plus booster doses funded individuals:

• pre- or post-splenectomy
• with functional or anatomic asplenia
• pre- or post-solid organ transplantation
• with complement deficiency (acquired or inherited)
• who are HIV-positive.

Two primary doses are funded for individuals aged from 12 months:

• post-haematopoietic stem cell transplantation
• prior to planned and following immunosuppression for longer than 28 days.

There is an increased risk of fever and medically attended fever-related events, such as sepsis screening and febrile seizures associated with MenB in some children age under 2 years.[4, 30, 31, 32, 33] These events peaked at six hours post-vaccination and generally subsided by day 3. Fever of at least 38°C was observed in 80 percent of infants who received MenB and routine vaccines concomitantly, and 71 percent who had MenB and routine vaccines separately, compared with 51 percent who receive routine vaccines only.[34, 35] Paracetamol was show to reduce the incidence of fever. Prophylactic paracetamol is recommended from 30 minutes prior to or immediately after vaccination, then two further doses can be given four to six hours apart for children aged under 2 years. Some infants will still develop a fever and/or injection-site pain even though they have received paracetamol doses.[36]

In clinical trials, most infants and young children had at least one solicited adverse reaction (84–97 percent)[35], including injection-site tenderness and irritability. Adolescents and adults may experience localised pain, nausea, myalgia, malaise, mild fever and headache.

Potential adverse reactions after meningococcal conjugate vaccines include localised injection-site pain, irritability, headache, malaise and fatigue.[26, 37] The safety profile of all the MenACWY vaccines are very similar.[26, 27, 28] In infants, unusual crying, irritability, drowsiness and vomiting have been reported in clinical trials.[24, 39] Fever is reported by 2–5 percent of adolescents and less than 10 percent of infants who receive MenACWY. Concurrent administration with routine vaccines did not increase solicited systemic responses in young children (when given with PCV13) but was slightly increased in adolescents (with Tdap and HPV) during clinical trials of MenQuadfi.[24, 38, 39]

Guillain–Barré syndrome

There is no evidence of an association between meningococcal conjugate vaccines and GBS. An early report in the US of a suspected temporal association between MenACWY (Menactra) and GBS was followed by a large retrospective cohort study in the US that found no evidence of an increased risk of GBS following administration of MenACWY.[28, 40] If indicated, meningococcal conjugate vaccines may be administered to individuals with a history of GBS.[41]

Close contacts of cases of any group (including group A, B, C, W or Y) meningococcal disease may be offered both MenB and MenACWY meningococcal vaccines (see section 13.5).

See below for the use of the vaccines for the control of outbreaks, as initiated by the local public health service.

When there is an outbreak of meningococcal disease of a specific vaccine group, an immunisation programme may be recommended and funded for a defined population. The local medical officer of health will determine the necessary action in discussion with Health New Zealand.

For more details on control measures, refer to the ‘Neisseria meningitidis invasive disease’ chapter of the Communicable Disease Control Manual .

1. Campbell H, Parikh SR, Borrow R, et al. Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016. Euro Surveill, 2016. 21(12).
2. Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis, 2015. 60(4): p. 578-85.
3. Cohn A ,MacNeil J. The Changing Epidemiology of Meningococcal Disease. Infect Dis Clin North Am, 2015. 29(4): p. 667-77.
4. Harrison LH, Granoff DM ,Pollard AJ. 2018. Meningococcal Capsular Group A, C, W and Y conjugate vaccines, in Plotkin's Vaccines (7th edition), Plotkin SA, Orenstein W, Offit P, and Edwards K (eds). Elsevier: Philadelphia, US.
5. Rubilar PS, Barra GN, Gabastou JM, et al. Increase of Neisseria meningitidis W:cc11 invasive disease in Chile has no correlation with carriage in adolescents. PLoS One, 2018. 13(3): p. e0193572.
6. Wang B, Santoreneos R, Giles L, et al. Case fatality rates of invasive meningococcal disease by serogroup and age: A systematic review and meta-analysis. Vaccine, 2019. 37(21): p. 2768-2782.
7. Meningococcal Disease Surveillance Group. Analysis of endemic meningococcal disease by serogroup and evaluation of chemoprophylaxis. J Infect Dis, 1976. 134(2): p. 201-4.
8. Neal KR, Nguyen-Van-Tam JS, Jeffrey N, et al. Changing carriage rate of Neisseria meningitidis among university students during the first week of term: cross sectional study. BMJ, 2000. 320(7238): p. 846-9.
9. Bruce MG, Rosenstein NE, Capparella JM, et al. Risk factors for meningococcal disease in college students. JAMA, 2001. 286(6): p. 688-93.
10. Nelson SJ, Charlett A, Orr HJ, et al. Risk factors for meningococcal disease in university halls of residence. Epidemiol Infect, 2001. 126(2): p. 211-7.
11. Christensen H, May M, Bowen L, et al. Meningococcal carriage by age: a systematic review and meta-analysis. The Lancet Infectious Diseases, 2010. 10(12): p. 853-61.
12. Peterson ME, Li Y, Shanks H, et al. Serogroup-specific meningococcal carriage by age group: a systematic review and meta-analysis. BMJ Open, 2019. 9(4): p. e024343.
13. Institute of Environmental Science and Research (ESR). 2024 Invasive meninogoccal disease report, January - December 2023. ESR: Porirua, New Zealand. URL: www.esr.cri.nz/meningococcal-reports
14. Ladhani SN, Andrews N, Parikh SR, et al. Vaccination of Infants with Meningococcal Group B Vaccine (4CMenB) in England. N Engl J Med, 2020. 382(4): p. 309-317.
15. McMillan M, Wang B, Koehler AP, et al. Impact of Meningococcal B Vaccine on Invasive Meningococcal Disease in Adolescents. Clinical Infectious Diseases, 2021.
16. McNamara LA, Thomas JD, MacNeil J, et al. Meningococcal Carriage Following a Vaccination Campaign With MenB-4C and MenB-FHbp in Response to a University Serogroup B Meningococcal Disease Outbreak-Oregon, 2015-2016. J Infect Dis, 2017. 216(9): p. 1130-1140.
17. Soeters HM, Whaley M, Alexander-Scott N, et al. Meningococcal carriage evaluation in response to a serogroup B meningococcal disease outbreak and mass vaccination campaign at a college – Rhode Island, 2015 – 2016. Clin Infect Dis, 2017. 64(8): p. 1115-1122.
18. Marshall HS, Lally N, Flood L,Phillips P. First statewide meningococcal B vaccine program in infants, children and adolescents: evidence for implementation in South Australia. Med J Aust, 2020.
19. Deceuninck G, Lefebvre B, Tsang R, et al. Impact of a mass vaccination campaign against Serogroup B meningococcal disease in the Saguenay-Lac-Saint-Jean region of Quebec four years after its launch. Vaccine, 2019. 37(31): p. 4243-4245.
20. Ladhani SN, Campbell H, Andrews N, et al. First real world evidence of meningococcal group B vaccine, 4CMenB, protection against meningococcal group W disease; prospective enhanced national surveillance, England. Clin Infect Dis, 2020.
21. GlaxoSmithKline NZ Ltd, New Zealand Data sheet: Bexsero multicomponent meningococcal group B vaccine (recombinant, adsorbed). 2020, Medsafe.
22. Martinón-Torres F, Bernatowska E, Shcherbina A, et al. Meningococcal B vaccine immunogenicity in children with defects in complement and splenic function. Pediatrics, 2018. 142(3).
23. Martinón-Torres F, Bertrand-Gerentes I ,Oster P. A novel vaccine to prevent meningococcal disease beyond the first year of life: an early review of MenACYW-TT. Expert Review of Vaccines, 2021. 20(9): p. 1123-1146.
24. sanofi-aventis New Zealand. New Zealand datasheet: MenQuadfi. Medsafe; [updated 22 September 2022]; URL: https://www.medsafe.govt.nz/Profs/Datasheet/m/Menquadfiinj.pdf. (accessed 1 December 2022)
25. Chang LJ, Hedrick J, Christensen S, et al. A Phase II, randomized, immunogenicity and safety study of a quadrivalent meningococcal conjugate vaccine, MenACYW-TT, in healthy adolescents in the United States. Vaccine, 2020. 38(19): p. 3560-3569.
26. Hedari CP, Khinkarly RW ,Dbaibo GS. Meningococcal serogroups A, C, W-135, and Y tetanus toxoid conjugate vaccine: a new conjugate vaccine against invasive meningococcal disease. Infect Drug Resist, 2014. 7(3 April): p. 85-99.
27. Mbaeyi SA, Bozio CH, Duffy J, et al. Meningococcal Vaccination: Recommendations of the Advisory Committee on Immunization Practices, United States, 2020. MMWR Recomm Rep, 2020. 69(9): p. 1-41.
28. Centers for Disease Control and Prevention. 2013. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). Morbidity and Mortality Weekly Report: Recommendations and Reports. 62(2): p. 1–28. https://www.cdc.gov/mmwr/pdf/rr/rr6202.pdf (accessed 27 February 2020)
29. Drugs and Lactation Database (LactMed). 2006-. Meningococcal Vaccines. in Drugs and Lactation Database (LactMed). Bethesda MD. URL: https://www-ncbi-nlm-nih-gov.ezproxy.auckland.ac.nz/books/NBK501014/. (accessed 1 December 2022)
30. Vesikari T, Esposito S, Prymula R, et al. Immunogenicity and safety of an investigational multicomponent, recombinant, meningococcal serogroup B vaccine (4CMenB) administered concomitantly with routine infant and child vaccinations: results of two randomised trials. The Lancet, 2013. 381(9869): p. 825-35.
31. Vesikari T, Prymula R, Merrall E, et al. Meningococcal serogroup B vaccine (4CMenB): Booster dose in previously vaccinated infants and primary vaccination in toddlers and two-year-old children. Vaccine, 2015. 33(32): p. 3850-8.
32. Harcourt S, Morbey RA, Bates C, et al. Estimating primary care attendance rates for fever in infants after meningococcal B vaccination in England using national syndromic surveillance data. Vaccine, 2018. 36(4): p. 565-571.
33. Zafack JG, Bureau A, Skowronski DM,De Serres G. Adverse events following immunisation with four-component meningococcal serogroup B vaccine (4CMenB): interaction with co-administration of routine infant vaccines and risk of recurrence in European randomised controlled trials. BMJ Open, 2019. 9(5): p. e026953.
34. Gossger N, Snape MD, Yu L-M, et al. Immunogenicity and tolerability of recombinant serogroup B meningococcal vaccine administered with or without routine infant vaccinations according to different immunization schedules. JAMA, 2012. 307(6).
35. Martinón-Torres F, Safadi MAP, Martinez AC, et al. Reduced schedules of 4CMenB vaccine in infants and catch-up series in children: Immunogenicity and safety results from a randomised open-label phase 3b trial. Vaccine, 2017. 35(28): p. 3548-3557.
36. De Serres G, Billard MN, Gariépy MC, et al. Short-term safety of 4CMenB vaccine during a mass meningococcal B vaccination campaign in Quebec, Canada. Vaccine, 2018. 36(52): p. 8039-8046.
37. American Academy of Pediatrics. 2018. Meningococcal disease. in Red Book: 2018 Report of the Committee on Infectious Diseases, Kimberlin D, Brady M, Jackson M, and Long S (eds). Elk Grove Village, IL. p. 551-561. URL: https://redbook.solutions.aap.org/redbook.aspx. (accessed 15 April 2020)
38. Pina LM, Bassily E, Machmer A, et al. Safety and immunogenicity of a quadrivalent meningococcal polysaccharide diphtheria toxoid conjugate vaccine in infants and toddlers: three multicenter phase III studies. Pediatric Infectious Disease Journal, 2012. 31(11): p. 1173-83.
39. Marshall GS, Pelton SI, Robertson CA,Oster P. Immunogenicity and safety of MenACWY-TT, a quadrivalent meningococcal tetanus toxoid conjugate vaccine recently licensed in the United States for individuals ≥2 years of age. Hum Vaccin Immunother, 2022: p. 2099142.
40. Velentgas P, Amato AA, Bohn RL, et al. Risk of Guillain-Barré syndrome after meningococcal conjugate vaccination. Pharmacoepidemiol Drug Saf, 2012. 21(12): p. 1350-8.
41. Australian Technical Advisory Group on Immunisation. 2018. Australian Immunisation Handbook (ed.), Canberra: Australian Government Department of Health. URL: https://immunisationhandbook.health.gov.au/ (accessed October 2019)